ArticleCanadian journal of psychiatry. Revue canadienne de psychiatrie2015
Who pioneered the use of antipsychotics in North America?
Article in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Infra-Low Frequency Neurofeedback rapidly ameliorates schizophrenia symptoms: A case report of the first session.Frontiers in human neuroscience · 2022Article
- Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry.Therapeutic advances in psychopharmacology · 2020Article
- The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.Frontiers in pharmacology · 2020Article
- The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Article
- Learning soft skills the hard way: Historiographical considerations on the cultural adjustment process of German-speaking émigré neuroscientists in Canada, 1933 to 1963.Journal of the history of the neurosciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNeuroleptics were introduced into North America 60 years ago. The credit for this advance is generally accorded to Heinz Lehmann. I sought to explore whether Lehmann really was the first North American psychiatrist to study the effects of chlorpromazine (CPZ) and to provide a more balanced view of its application in a clinical context.
methodI searched for historical documents and published articles in several libraries and interviewed psychiatrists active from 1952-1970.
resultsThe first article in English was published in the July volume of the Archives of Neurology and Psychiatry in 1954 (n=71). Another article, written in French by Roland Saucier and published in a journal called Le Saguenay Médical, also described the effects of CPZ on a Canadian psychiatric population in August 1954 (n>200). However, the first prescription for CPZ was written by Roland Saucier, who brought the product back from Paris after a fellowship there. Ruth Kajander, in Ontario, was also one of the first prescribers of this drug, following her study of its use in anesthesia and a publication in the proceedings of a symposium.
conclusionThe contents of the 2 naturalistic studies were compared. Lehmann's study started 1 month before that of Saucier. Lehmann was the first North American psychiatrist to publish an article on CPZ, but Roland Saucier nevertheless made an important contribution, being the first to prescribe this drug in North America and reporting results for a study with a sample size 3 times that of Lehmann's study.
Indexed as
Identifiers
25886681PMC4418623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.